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Simple Summary: Thymoma is a tumor of the cranial mediastinum rarely reported in dogs and
should be differentiated from mediastinal lymphoma. CT and fine-needle aspirates or core biopsies
are helpful in differential diagnosis, but flow cytometry may improve the pre-operative diagnostic
ability. In thymomas, paraneoplastic syndromes such as myasthenia gravis and hypercalcemia may
develop concurrently with the tumor. Their role as prognostic factors is not well determined. Surgical
excision is the treatment of choice, but adjuvant radiotherapy and/or chemotherapy may prolong
survival in cases of incomplete excision or if a thymic carcinoma is diagnosed. Local recurrence and
metastasis are infrequently reported; therefore, a long survival is expected if the tumor is completely
excised or if adjuvant therapy is undertaken. This article reports the authors’ experience with 28 dogs
affected by 18 thymomas and 10 thymic carcinomas surgically treated from January 2000 to August
2021. The median overall survival time of the entire population was 1137 days; the median disease-
free time was 903 days. Dogs with thymic carcinomas had significantly shorter disease-free intervals
and shorter, although not statistically significant, survival times. Dogs with Masaoka Stage III tumors
had worse outcomes.
Abstract: Thymoma is a tumor rarely reported in dogs and should be differentiated from mediastinal
lymphoma. Clinical signs may have a late onset, and thymoma is often diagnosed when symptoms
related to the space-occupying effect or paraneoplastic syndromes occur. CT and fine-needle aspirates
or core biopsies are helpful in differential diagnosis, but flow cytometry may improve the pre-
operative diagnostic ability. Concurrent paraneoplastic syndromes such as myasthenia gravis and
hypercalcemia have been reported; however, their role as prognostic factors is not well determined.
Surgical excision is the treatment of choice; adjuvant radiotherapy and/or chemotherapy may
prolong survival in cases of incomplete excision or when a thymic carcinoma is diagnosed. Local
recurrence and metastasis are infrequently reported; therefore, a long survival time is expected if the
tumor is completely excised or if adjuvant therapy is undertaken. This article reports the authors’
experience with 28 dogs affected by 18 thymomas and 10 thymic carcinomas. The median overall
survival in this series was 1173 days, and the median disease-free interval was 903 days. Dogs
with thymic carcinoma had significantly shorter disease-free intervals and shorter, although not
statistically significant, survival times. Dogs with Masaoka Stage III tumors had worse outcomes.
Keywords: dog; thymoma; canine thymic carcinoma; paraneoplastic myasthenia gravis; hypercalcemia
of malignancy; thoracic surgery
1. Introduction
Thymoma is an uncommon canine tumor but is the second most common neoplasm
of the cranial mediastinum of dogs, after lymphoma [1]. A similar incidence is reported
in both cats and human beings, in which it represents up to 50% of cranial mediastinal
tumors [2,3].
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Clinical signs may be presented late, since they are mainly related to the space-
occupying effect of the tumor itself; therefore, if they are not an incidental finding, diagnoses
are often made when the mass is already of a relevant size, sometimes influencing the
therapeutic options. In some instances, clinical signs related to paraneoplastic syndromes
such as myasthenia gravis (MG) and hypercalcemia of malignancy are the complaints
at presentation.
One of the critical steps in the management of thymic epithelial tumors (TET)—as
they are named in human medicine [4]—is definitive diagnosis, which requires histol-
ogy in most cases, particularly for a differential diagnosis from mediastinal lymphoma.
Imaging, cytology, and flow cytometry [5–7] may help in achieving the diagnosis, since
some symptoms differ from those of mediastinal lymphoma, although this is not always
straightforward (Figure 1).
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Figure 1. CT imaging of a large thymoma (a) and a ly phoma (b) occupying most of the cranial
ventral mediastinum of two dogs. The heterogeneous, cystic appearance of the thymic tumor
compared with lymphoma is evident.
Thymomas may have a more benign or malignant behavior depe ding on the type of
growth—expansive or infiltrative—rather than on the histologic s t ; i teristic
influences invasion into surrounding tis ues, such as the lungs, pericardium, and blood
ves els, and thus the resectability of the mas .
The therapy of choice in both human and veterinary medicin is surgery [8–12]. If
the thymoma can be completely removed and the capsule is not invaded, the prognosis is
good [11].
Due to the low i idence of the tumor, only a few reports found in the lit rature—
main y multi-institutional—account for a large number of cases [7–10,13]. This cas series
r presents th experience of the authors with canine TET in the last 20 years. A comparison
with what has been reported in the literature within the same time interval is reported.
2. Materials and Methods
Dogs that underwent open thoracic surgery for the excision of a mass histologically
diagnosed as a thymic epithelial tumor between January 2000 and August 2021 at the
Veterinary Teaching Hospital of Grugliasco (Turin, Italy) were included in this study. The
collected data included signalment, clinical (blood work and FNA biopsy of the mass),
diagnostic imaging work up (thoracic radiographs, ultrasound, and/or CT of the chest),
type of surgery, other therapies adopted, and the presence of paraneoplastic syndromes at
diagnosis or developed during the follow-up. Dogs were included if a diagnosis of TET
was histologically confirmed and they had a follow-up of at least 5 months. The histological
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diagnosis was based on the initial pathology report, which was made for the majority of
cases by the same non-board-certified pathologist; no revision of the initial report was
made by a board-certified pathologist.
During the time lapse considered, each dog admitted to the hospital for clinical
signs related to the presence of a mediastinal or thoracic mass and/or of paraneoplastic
syndromes related to mediastinal masses received a clinical examination, complete blood
work, and three-view thoracic radiographs. Once presumptive diagnoses of the mediastinal
mass had been achieved, an ultrasound-guided fine-needle aspiration of the mass was
attempted. In more recent cases, a total body contrast-enhanced CT was also performed.
When a definitive differential diagnosis from mediastinal lymphoma could not be reached
by cytology and flow cytometry, exploratory thoracic surgery was performed.
Chemotherapy and radiotherapy (RT) were offered when a final diagnosis of thymic
carcinoma was obtained, regardless of the completeness of excision. The chemotherapy
drugs used included carboplatin, cyclophosphamide, and vincristine. The latter was mainly
used in a neoadjuvant setting to achieve a cytoreduction in the tumor before surgery.
After surgery, the animals were hospitalized until the chest drain was in place, gener-
ally for 1 to 3 days.
The follow-up included a clinical examination, thoracic radiographs, and an evaluation
of the signs of paraneoplastic syndromes every 4 months for the first year and every
6 months in the second year.
Data from long-term follow-up were obtained by phone calls to the owners or referring
veterinarian in cases where they were not otherwise available.
The survival analysis was conducted using Kaplan–Meier’s product of survival prob-
ability curves. The log rank test was used to compare the survival curves. The analysis
was conducted using the GraphPad 9 Prism program. The disease-free (DF) interval was
considered the time from surgery to tumor recurrence or metastasis, and the overall sur-
vival (OS) time was calculated from the day of surgery to death from any cause. Dogs
that died from non-tumor related causes, that were lost to follow-up, or that were alive
at the end of the study were censored. Dogs that died within 1 week of surgery were
considered perioperative deaths. Dogs that died because of paraneoplastic syndromes
were considered as having died from the tumor. The canine population was divided into
two groups based on a pathology report of thymoma or thymic carcinoma, and a survival
analysis was conducted on the two populations. The same analysis was conducted on dogs
divided according to Masaoka stages [14].
3. Results
3.1. Signalment and Clinical Findings
In this study, 28 dogs were included, of which 10 were males (one castrated) and
18 were females (seven spayed); the median age at presentation was 10 years (range:
6–13 years). Twelve dogs were mixed-breed animals, three were Rottweilers, two were
Fox terriers, two were Labrador retrievers; and the number of Akita Inus, Alsatians (Ger-
man shepherds), American Staffordshire terriers, Beagles, Dobermann pinschers, Golden
retrievers, Lagottos, Shi-tzus, and Yorkshire terriers was one each. Some of these animals
with thymic carcinoma were included in the study published by Yale et al. [9].
• Diagnostics: contrast-enhanced CT of the thorax without an angiogram was per-
formed and available in 18 dogs; in older cases, medical records only reported three-
view thoracic radiographs and thoracic ultrasounds for guidance in FNA of the
mediastinal mass.
• Paraneoplastic syndromes: MG was diagnosed in two dogs (7.1%) before tumor removal
and in three dogs (10.7%) after tumor excision, one of which was in the form of
the focal megaesophagus; MG was confirmed by AchR antibody titers in four dogs
and was presumed on the basis of the Tensilon test in one dog. The syndrome was
resolved after surgery in one case and persisted in the other one. Pyridostigmine was
administered to the animals in the generalized form. Hypercalcemia was diagnosed
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in two dogs (7.1%), both of which were affected by a thymic carcinoma, and one of
which developed postoperative hypocalcemia that was resolved with symptomatic
treatment after 15 days of hospitalization. The other dog presented with a large
mediastinal mass and clinical signs of hypercalcemia, which was treated medically by
the referring veterinarian with furosemide for 3 months before surgery was accepted
by the owners. The syndrome was resolved after surgery, and it recurred at the time of
tumor recurrence. Parathyroid hormone-related peptide (PTH-rp) was not evaluated
in either animal.
• One dog was first seen for severe immune-mediated anemia that was treated by
immunosuppressive doses of prednisone and cyclophosphamide and did not recur
after extirpation of the tumor. The final diagnosis was thymoma, but the tumor
recurred after 366 days and the dog was lost to follow up at that time.
• Five dogs (17.8%) had a concurrent tumor or developed one in the course of their life:
one brochioloalveolar carcinoma, one lung squamous cell carcinoma, one squamous
cell carcinoma of the digit, one cutaneous hemangiosarcoma, and one solid carcinoma
of the frontal sinus. Brochioloalveolar carcinoma was the cause of death in one dog.
3.2. Therapy
Nineteen (65.5%) median sternotomies (Figure 2) and 10 (34.5%) intercostal thoraco-
tomies were performed (one dog had a recurrence removed by median sternotomy after
the excision of the primary tumor by the intercostal approach). Two dogs required a partial
lung lobectomy to excise the tumor.
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Figure 2. CT (a) and gross (b) appearance of a thymoma removed by stern tomy. The heterogeneity
of the imaging is also visible macroscopically. The tumor could be removed en bloc.
Complications of the surgery included seroma formation in seven cases of median
sternotomy, five of which required wound revision; fatal pulmonary thromboembolism in
one case; and left subclavian artery rupture in one case, which was ligated and caused the
dog to be lame on the left front leg for some days after surgery, which finally improved
within 2 weeks. One dog died immediately after surgery because of heart failure, and one
was euthanized intraoperatively because the tumor appeared to be non-resectable.
• Neoadjuvant and adjuvant treatments: chemotherapy was administered to seven dogs
(25%), five postoperatively and two before surgery. The dog affected by immune-
mediated anemia received cyclophosphamide (200 mg/m2/week) and prednisone
(starting from 2 mg/kg/day for 1 week, tapering the dose in the following weeks)
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before surgery, which partially resolved the anemia. The other dog had an erroneous
first diagnosis of lymphoma; therefore, a COP protocol (cyclophosphamide, vincristine,
and prednisone) was started by the referring veterinarian, without success.
The dog with hypercalcemia and thymic carcinoma received carboplatin (300 mg/m2)
at the time of tumor recurrence, 60 days after surgery. A partial response was achieved,
and the hypercalcemia was resolved. He is currently under treatment at the time of writing,
but a complete response was not achieved, and the owners refused RT.
3.3. Histopathology Reports
Eighteen cases (64.3%) were diagnosed as thymoma (Types A, AB, and B1-2 of the
WHO classification [15]), one (3.6%) as atypical thymoma (Type B3), and 10 (35.7%) as
thymic carcinoma (Type C). Data on the completeness of excision were available in only
five cases, of which three were completely excised; in two cases, the margins (the tumor
capsule) were infiltrated, but only one recurred 60 days after surgery. In 25 dogs, the
Masaoka staging system (Table 1) [14] could be retrospectively applied and resulted in
eight Stage I, seven Stage II, and ten Stage III tumors. Metastases to regional lymph nodes
were not detected in any of the excised nodes (five cases). Necropsy was performed only in
one case of a dog that developed metastases 12 days after surgery and revealed metastasis
to the liver, spleen, and pancreas.
Table 1. The Masaoka staging system [14].
Stage Description
I Completely encapsulated
II Invades the capsule, either microscopically or macroscopically
III Invades the neighboring organs, with or without great vessel involvement
IV Metastatic, either locally on the thoracic mesothelium or distantly
3.4. Follow-Up
Seven dogs (25%) developed recurrence after 60 to 903 days (median: 60 days), two of
which were diagnosed as thymoma. Two dogs (7.1%), one with a thymic carcinoma and
one with a thymoma, developed metastasis after 289 and 12 days, respectively; the former
developed lung metastasis diagnosed by thoracic radiographs, and the second developed
metastasis to the abdominal organs.
One of the cases that developed a recurrence after 930 days from the first excision had a
second surgery performed and survived for a total of 1340 days before dying spontaneously,
probably due to the consequences of the megaesophagus and focal MG that developed
1 month before death.
According to the Kaplan–Meier survival curves, the median disease-free time of the
entire population was 903 days (range: 0–2124 days) and the median overall survival time
was 1137 days (range: 0–2124 days). Five dogs were alive at the end of the study after 145–
809 days (median: 293 days). One of these dogs had a large thymic carcinoma with vascular
invasion that had been incompletely resected and recurred macroscopically after 2 months;
he is currently under carboplatin chemotherapy but not in complete remission. Three
dogs (10.7%) died from causes not related to the tumor after 898, 912, and 2124 days; in
particular, the causes of death were metastasis of a concurrent brochioloalveolar carcinoma,
cardiomyopathy, and sudden death of unknown origin. Fourteen dogs (50%) died because
of the tumor (four (14.3%) perioperatively) after 0 to 1340 days (median: 40.5 days), and six
(21.4%) were lost to follow-up after 220–1358 days (median: 498.5 days), without signs of
tumor recurrence or metastasis at the last follow-up.
When comparing dogs with thymic carcinoma (10 cases) against the ones with less
aggressive histotypes, the DF interval was significantly shorter (p = 0.028) for thymic
carcinomas (a median of 84.5 days vs. median not reached). Overall survival did not differ
significantly (p = 0.076), although the median survival for thymic carcinomas was 291 days
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compared with the 1340 days achieved by less aggressive forms. The 1- and 2-year survival
rates of the entire population were 58.3% and 38%, respectively.
The Kaplan–Meier survival curves for the entire population and for the group of
thymomas and thymic carcinomas are shown in Figures 3 and 4.
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When considering the Masaoka stage [14], the median survival of the eight Stage I 
dogs was 1732 days; two dogs were alive at the end of the study (after 145 and 417 days), 
and one dog died because of the tumor. Regarding the seven Stage II dogs, the median 
survival was not reached (mean: 424.8 days); one dog was alive after 809 days, and three 
died because of the tumor after 25, 120, and 220 days, respectively. Worse outcomes were 
observed in the 10 dogs with Stage III tumors, with a median survival of 291 days; eight 
dogs died from the tumor after 0 to 714 days, and two dogs are alive after 167 and 293 
days. Table 2 shows the survival of dogs according to Masaoka stage, and Figure 5 shows 
the Kaplan–Meier survival curves of the three groups; the difference in survival is statis-
tically significant between Stages I and III (p = 0.0049) but not between Stages II and III (p 
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T ble 2. Survival of dogs according to the Masaoka stage [14].
Stage N. of Cases Median Survival(Days) Alive
Dead from the
Tumor
Lost to Follow-Up/Dead from
Unrelated Causes
I 8 1732 2 1 4
II 7 n.r. 1 3 3
III 10 291 2 8 0
IV 0 - - - -
n.r. = not reached.
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MG was not resolved in two cases but was managed with lifelong pyridostigmine
administration; hypercalcemia was resolved after surgery but recurred in the dog with
thymic carcinoma at the time of tumor recurrence. The immune-mediated anemia did not
recur after tumor extirpation, but the dog was lost to follow-up 366 days after surgery at
the time of tumor recurrence.
4. Discussion
Thymoma is the second most common tumor of the cranial mediastinum in dogs, after
lymphoma; nonetheless, it is infrequently reported [1]. Thymic tumors usually affect older
animals, with a mean age of 9 to 10 years, although one case of a 1-year-old pug has been
described [16]. There is no sex predilection, and some breeds seem to be overrepresented,
such as Labrador retrievers, Alsatians, and Golden retrievers [2,7,8,10,13,17]. In the pre-
sented case series, the median age at presentation was 10 years, and no breed predilection
was found except for mixed-breed dogs, which were the most represented.
Thymomas develop from the epithelial cells of the medulla of the thymus, but variable
numbers of small lymphocytes may be present, thus making a differential diagnosis from
lymphoma challenging by cytology alone. Small amounts of mast cells and eosinophils can
also be observed. This difficulty may have been the cause of the initial diagnostic error that
occurred in one case in this series. In fact, two main issues are present when differentiating
thymomas from other mediastinal masses: the macroscopic differentiation by imaging from
space-occupying masses, and microscopic differentiation from lymphoma before histology
of the resected mass is performed. The differential diagnosis should be primarily versus
ediastinal lymphoma, but other space-occupying masses should also be ruled out, such
as branchial cysts, ctopic thyroid or parat yroid t m rs, chemodectoma, thymic cysts,
met static neoplasia, absces es, granuloma , and other rarer thymus dis rders such as
thymolipoma and thymofibrolipoma [18–21].
Imaging is critical for evaluating the extent of the tumor, guide biopsies, and planning
the surgery. The main preoperative concerns relate to the location of the mass (pulmonary
vs. mediastinal), and its invasion into adjacent organs, especially the main blood vessels.
Three-view thoracic radiographs are the first step to determining the presence of a
mediastinal mass and pleural effusion or displacement of the heart silhouette. In animals
with megaesophagus, the enlargement of the organ, the ventral displacement of the trachea,
or signs of aspiration pneumonia may be seen. The older cases in this series only had
thoracic radiographs performed, and this may have been the cause of the difficulty in
clearly defining the extent of the tumor before surgery.
Thoracic ultrasound is a further step that allows for better characterization of the
mass and the performance of guided fine-needle or core biopsies [22]. FNA was always
performed in this case series, although it did not always allow for differentiation from
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mediastinal lymphoma. Core biopsies have never been proposed due to the surgeon’s
choice. In a study comparing 30 dogs and 5 cats with thymoma and 12 dogs and 3 cats with
mediastinal lymphoma, Patterson and Marolf [23] found that echogenicity significantly
differentiated the two tumor types, with thymoma being more heterogeneous compared
with lymphoma.
Diagnostic imaging should be completed using computed tomography (CT), which
is better for detecting the presence of metastases and for evaluating the size and extent
of the tumor in the neighboring organs and vessels compared with radiographs [7,17,24].
CT was performed in 18 out of 28 dogs (64.3%) in this series, but an angiogram was
never performed, which may have allowed us to identify the cases with larger blood
vessel tumor involvement. In fact, three of the four perioperative deaths occurred in older
cases that did not have CTs performed. Nevertheless, the perioperative mortality was not
different from what has been reported by other authors [9,10]. Recent studies have reported
better results for the ability of CT to detect vascular invasion [7] compared with older
studies [24], although this parameter was not related to outcomes. Nevertheless, 5 of the
10 dogs with vascular invasion in the study of Scherrer and coworkers [24] died during the
perioperative period. Both studies recommend venography during CT to better evaluate
vessel involvement. Regarding vascular invasion, Reeve and colleagues [17] affirmed that
the identification of vascular invasion was more difficult when a tumor thrombus was not
present or when the vessel was markedly compressed by the mass itself. This fact should
be considered when planning surgery on the basis of the CT results.
Pintore et al. [6] found a good correlation between cytological and histological evalua-
tions of mediastinal masses in dogs and cats obtained by using either the blind technique,
ultrasound, or CT, provided that the cytological samples were of good quality. Comparable
results were found by Robat et al. [8], in which the cytology results were in agreement
with the histology in 40 of 42 samples, and by Rick et al. [25], who found a concordance
of 85%. To improve the ability of cytology in reaching a diagnosis, flow cytometry has
been proposed as a valid approach to differentiating thymoma and lymphoma in dogs [5].
More than 80% of thymocytes express CD4 and CD8 markers, and this phenotype is
different from other peripheral lymphocytes present in other organs. Therefore, it may
be considered a way to differentiate thymoma from any other neoplastic masses in the
cranial mediastinum in most cases. The presence of >10% of CD4+CD8+ cells in the small
lymphocyte population was deemed 100% specific for thymoma in the study by Lana
et al. [5]. As described for cytology, an appropriate sampling technique is important for
retrieving a valuable sample. Nevertheless, two studies, by Burton and colleagues [26]
and by Wikander and colleagues [27], reported a case of the CD4–CD8 double-negative
immunophenotype of thymoma, which warns of the need to consider other diagnostic
tools to prove or exclude the diagnosis of thymoma in such cases. In the cases presented
here, flow cytometry was used only in two dogs, one of which led to the diagnosis of
lymphoma for the first time and thymoma once the analysis was repeated.
Histology allows for a final diagnosis. In humans, thymic tumors are referred to
as thymic epithelial tumors (TET), including both benign and malignant histotypes [4].
The most widely used staging system in humans is the Masaoka and Monden staging
scheme [14], which considers tumor invasiveness as the main indicator of malignancy
(Table 1). This scheme has been proposed to be also used by veterinary pathologists [8].
Canine TET staging may therefore refer to the Masaoka scheme [14], based on di-
agnostic imaging and the histological characteristics of the tumor, and to the modified
WHO classification of the histologic grade [15,28]. In this case series, the Masaoka classi-
fication was applied retrospectively to cases where adequate information was available.
This represents a limitation of the study, as is the lack of a revision of the histology by a
board-certified pathologist. In fact, the occurrence of metastasis in one case diagnosed as
thymoma may cause doubt regarding a misdiagnosis of this tumor. Moreover, the histol-
ogy reports of older cases did not allow for an up-to-date classification into the different
subtypes of thymoma, which were grouped as “thymoma”, unless a thymic carcinoma was
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diagnosed. The Masaoka classification revealed that Stage III tumors have a significantly
worse prognosis compared with lower-stage tumors, in accordance to what has been found
by Robat and coworkers [8].
The role of paraneoplastic syndromes in the clinical outcome is not fully understood,
but aspiration pneumonia consequent to the presence of megaesophagus may worsen the
prognosis. MG may develop either before or after surgery and does not always improve
after tumor excision; therefore, the response of MG to medical treatments (pyridostig-
mine, corticosteroids, and other immunosuppressive drugs) may influence the long-term
survival. However, its role as a negative prognostic factor is controversial, as reported
by Zitz et al. [11], by Robat et al. [8], and by von Stade et al. [7]. In the present study,
paraneoplastic MG was observed in a lower number of cases compared with what was
reported by the literature (17.8% vs. 27–40%). In three cases, MG developed after tumor
removal and needed to be managed for a variable period of time before resolution. In two
cases, lifelong administration of pyridostigmine was necessary. The five dogs with MG
survived for 56 to 1340 days (median: 220 days); therefore, no correlation with survival can
be made. Nevertheless, complications of megaesophagus were the probable cause of death
for the dog that developed it in the postoperative period.
Hypercalcemia of malignancy may be found in dogs with thymoma as well as in
those with mediastinal lymphoma [29,30]. To confirm the paraneoplastic origin of this
condition, in addition to a high ionized calcium, the blood level of PTH-rp should be high;
in fact, the most accredited hypothesis considers the ectopic production of the parathyroid
hormone as the cause of hypercalcemia in these cases [30]. Concurrently, a low parathyroid
hormone blood level should be found. Two dogs in this series developed hypercalcemia of
malignancy, which was not confirmed by PTH-rp evaluation. The paraneoplastic syndrome
was resolved after tumor excision and recurred at the time of tumor recurrence.
Other hematological anomalies more rarely reported include anemia (immune-mediated
or aplastic in humans [3]) (2016 Bernard Thymoma Associated with Autoimmune Dis-
eases Autoimmunity Rev, n.d.), neutrophilia, lymphocytosis [26,31], thrombocytosis/
thrombocytopenia, and erythema multiforme [32]. Myocarditis and polymyositis have
also been reported [1]. Whether they are associated with a worse prognosis is still not well
established [7,8,13,33], although more recent articles have reported that MG was associ-
ated with a shorter survival in dogs [9,10,34,35]. One dog in this series had anemia as a
presenting clinical sign; the animal needed to be treated with immunosuppressive drugs
before undergoing surgery, and the anemia improved significantly after tumor excision.
The treatment of choice in both human and veterinary medicine is surgery [8–12]. If
the thymoma can be completely removed and the capsule is not invaded, the prognosis is
good [11]. The limitations of resectability have changed over the years but mostly depend
on the surgeon’s expertise in the field and confidence with this anatomic area, and on
access to appropriate surgical instrumentation and anesthesia techniques. Perioperative
mortality may be as high as 20% [10].The perioperative mortality in this study (14.3%) was
a little lower than this but may have been due to the small number of dogs included and to
selection bias relating to the retrospective nature of the study.
In a multi-institutional study conducted on 80 dogs and 32 cats, Garneau and cowork-
ers [10] approached the tumor by median sternotomy in 90 cases; lung lobectomy was
necessary in 21 dogs and four cats, whereas in four dogs, a section of the cranial vena cava
wall was removed. In this study, potential risk factors for perioperative mortality were
perioperative anemia and pleural effusion, while for long-term survival, perioperative
anemia, paraneoplastic syndrome, and incomplete histologic margins were found to be
prognostic. Tumor invasiveness was also considered to be a major prognostic factor for
perioperative mortality in other studies [11] but not for long-term survival.
Depending on the size of the tumor, the surgical approach may be by lateral intercostal
thoracotomy or median sternotomy. A major surgical complication of surgery is related to
excessive bleeding from great vessel lacerations. Vessel laceration also occurred in one dog
in this series, but it did not cause major complications. Seroma and suture dehiscence was
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the most common complication that occurred in dogs undergoing median sternotomy in
this series, and required surgical revision in five of seven cases. This complication occurred
in 36.8% of all sternotomies performed, which is a rather relevant incidence. No clinical
factors could be found to be related to this complication, but the retrospective nature of the
study limited this analysis.
Tumor recurrence was reported in 17% [8] of cases; a second surgery could be per-
formed in most cases, leading to a prolonged survival time. In this series, the recurrence
rate was 25%; in one case, a second surgery was performed, and the dog had a long survival
(1340 days), which is in line with what has been reported in the literature. The higher
recurrence rate may be due to the size of the tumors, which was large in many cases, thus
limiting the possibility of complete excision.
Metastases may occur in regional intrathoracic lymph nodes and the lungs in up to
20% of cases [1] but are rarely diagnosed at presentation. Rare reports of metastasis to
other organs, such as the liver, have been reported [36]. One dog in this study developed
liver metastasis, which was diagnosed at necropsy; this dog had a diagnosis of thymoma,
but this finding may raise the suspicion of a diagnostic error.
In the case of large or incompletely excised tumors, radiation therapy and/or
chemotherapy may be performed in an adjuvant setting. Thymoma is considered a ra-
diosensitive tumor, especially the lymphocyte-rich subtype [33], and different protocols
have been proposed [33,37–39]. RT has been proposed as a monotherapy with a palliative
intent in inoperable tumors. In this case, the control of acute and late side effects is essential
for quality of life reasons. A hypofractionated protocol has been investigated with this
aim [38]. RT was proposed in the case of thymic carcinoma in the present study, regardless
of the completeness of excision, but was declined by all owners. This therapy could have
made some difference in the outcome in those cases, but the paucity of the facilities and
the high costs still limit its use, at least in some countries.
The role of chemotherapy in the treatment of canine thymoma is not well established
yet, since no prospective clinical trials have investigated this subject. In human medicine,
chemotherapy is proposed in cases that are inoperable, at an advanced stage, or have recur-
rent tumors [40]. The protocols more commonly used are based on platinum–anthracycline,
with or without etoposide, or platinum and taxanes [12,40]. Targeted therapies do not
seem to be effective, while immunotherapy with anti PD1/PDL-1 has produced promis-
ing results [40]. In dogs, chemotherapy has always been used as an adjuvant to surgery
or RT [8–11]; the most commonly used agents are carboplatin, doxorubicin, cyclophos-
phamide, vincristine, toceranib phosphate, and prednisone, alone or in different combina-
tions, or metronomic therapy. The results of the treatment are variable, and too few cases
have been reported to draw any reliable conclusions, although the same indication as for
human beings should probably be followed. Chemotherapy was administered in a few
cases, with different drugs (carboplatin, cyclophosphamide, and vincristine) and protocols
in this study; therefore, nothing can be said about its efficacy. The adjuvant administration
of carboplatin in a prospective study may be worth evaluating.
In some cases, a second non-thymic tumor may be diagnosed concurrently [8]. This
concurrence has also been described in humans, where a second non-thymic tumor may
develop in 8 to 28% of cases [4]. A second tumor developed in five dogs (17.8%) in this
study, concurrently or not with the thymoma. This event does not seem to have influenced
survival in this case series.
The prognosis for thymoma in dogs is mainly associated with the completeness of
excision, the invasion of the capsule, and the survival to surgery (because of perioperative
complications) [7–11]. Masaoka Stages III and IV but not histologic subtypes were con-
sidered a negative prognostic factor in Robat and coworkers’ study [8]. Additionally, in
this case series, Masaoka Stage III had a significantly shorter survival (median: 291 days)
compared with Stage I tumors (median: 1732 days).
Table 3 shows a summary of the outcomes of the cases included.
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Table 3. Outcome data of the 28 dogs included in the authors’ case series.











1 Mix no n.d. 5 Thymoma 898 898 Dead * 6
2 Mix no III Invasivethymoma 0 0 Dead
3 Mix no I Thymoma R 366 366 LFU
4 Rottweiler yes n.d. Thymoma 8 8 Dead
5 Mix no II Thymoma R 105 120 Dead
6 Rottweiler no I Thymoma 912 912 Dead *





no III Thymoma M 12 20 Dead
9 Fox terrier no I Thymoma 562 562 LFU
10 Mix Yes HC II Thymic k 7 1358 1358 LFU
11 Mix Yes III Thymic k R 417 417 Dead
12 Shi-tzu No III Thymoma 0 0 Dead
13 Mix Yes II Thymic k 7 7 Dead
14 Mix Yes I Thymoma 1231 1231 LFU
15 Mix Yes MG n.d. Thymic k 56 56 Dead
16 Akita Inu Yes I Thymoma 2124 2124 Dead *
17 Beagle Yes MG III Thymic k R 1025 1137 Dead
18 Labradorretriever Yes III Thymic k R/M 289 714 Dead
19 Goldenretriever Yes II Thymoma 435 435 LFU
20 Mix Yes II Thymic k 25 25 Dead
21 Fox terrier Yes II Thymoma 809 809 Alive






No MG II Atypicalthymoma 220 220 LFU
24 Yorkshireterrier Yes III Thymoma 293 293 Alive
25 Dobermanpinscher Yes MG I Thymoma 145 145 Alive
26 Rottweiler Yes HC III Thymic k R 60 167 Alive
27 Mix Yes III Thymic k 7 7 Dead
28 Mix Yes III Thymic k R 109 165 Dead
1 hypercalcemia; 2 myastenia gravis; 3 disease-free; 4 survival; 5 not determined; 6 dead from causes not related to the tumor; 7 carcinoma.
5. Conclusions
The small case series reported here is in line with what was previously described in
terms of the incidence of paraneoplastic syndromes and outcomes. Thymic carcinoma
was diagnosed in 10 cases (35.7%), a rather relevant percentage; nevertheless, two dogs
survived for 1137 and 714 days, and one was still alive after 167 days from surgery and
254 days from the initial diagnosis, meaning that, if surgical excision/debulking is feasible,
long-term survival may also be achievable for these dogs. Adjuvant RT may have improved
these data, but it was never accepted by owners. The lower mortality rate reported in this
series compared with that in the literature may be due to selection bias and the low case
numbers.
In conclusion, thymoma is a rare tumor in dogs that should be differentiated from
other space-occupying masses of the cranial mediastinum. Bulky tumors may be surgically
excised or debulked, and this can prolong survival, especially when adjuvant radiotherapy
is associated, while the role of chemotherapy is not completely defined.
Additionally, the resection of a recurring tumor may prolong survival. Paraneoplastic
syndromes usually regress after treatment; nonetheless, MG may not be resolved or even
develop after tumor removal but it could be managed medically. Megaesophagus may be a
more severe consequence to consider.
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DF and OS were longer than those reported by the literature, but this could be due
to the small number of cases and/or selection bias. Additionally, it may support the
conclusion that when surgical excision is possible and regular restaging of the thorax is
performed, long-term survival may be achieved.
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